DocSym
β
Searchsearch
Search
(Y49.6) Psychodysleptics [hallucinogens]
More details coming soon
41 630 in individuals diagnosis psychodysleptics [hallucinogens] confirmed
2 424 deaths with diagnosis psychodysleptics [hallucinogens]
6% mortality rate associated with the disease psychodysleptics [hallucinogens]
Diagnosis psychodysleptics [hallucinogens] is diagnosed Women are 41.95% more likely than Men
12 083
Men receive the diagnosis psychodysleptics [hallucinogens]
710 (5.9 %)Died from this diagnosis.
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
29 547
Women receive the diagnosis psychodysleptics [hallucinogens]
1 714 (5.8 %)Died from this diagnosis.
Risk Group for the Disease psychodysleptics [hallucinogens] - Men aged 15-19 and Women aged 20-24
In Men diagnosis is most often set at age 5-9, 15-29, 35-54, 65-79
Less common in men the disease occurs at Age 0-5, 10-14, 30-34, 55-64, 80-95+Less common in women the disease occurs at Age 0-5, 80-84, 90-95+
In Women diagnosis is most often set at age 5-79, 85-89
Disease Features psychodysleptics [hallucinogens]
Absence or low individual and public risk
Psychodysleptics [hallucinogens] - what does this mean
Psychodysleptics, also known as hallucinogens, are psychoactive substances that alter perception, mood, and thought processes. they work by disrupting the action of certain neurotransmitters in the brain, resulting in changes in sensory perception, altered states of consciousness, and sometimes visual and auditory hallucinations.
What happens during the disease - psychodysleptics [hallucinogens]
Psychodysleptics, or hallucinogens, are drugs that affect the central nervous system, causing changes in perception, mood, and cognition. these drugs are thought to act on serotonin and dopamine receptors in the brain, resulting in increased activity of these neurotransmitters and causing hallucinations, altered states of consciousness, and other psychological and neurological symptoms. in addition, long-term use of these drugs can lead to changes in brain structure and function, resulting in cognitive impairment and other psychological disturbances.
Clinical Pattern
More details coming soon
How does a doctor diagnose
- Physical examination
- Neurological examination
- Psychological evaluation
- Laboratory tests
- Imaging tests
- Drug screening
- Toxicology tests
- Genetic tests
- Questionnaire about substance use
- Interview with family members
Treatment and Medical Assistance
Main goal of the treatment: To reduce the effects of hallucinogenic drugs on the patient.
- Educating the patient about the risks of hallucinogenic drugs
- Encouraging a healthy lifestyle, including a balanced diet and regular exercise
- Providing cognitive behavioral therapy to help the patient manage their symptoms
- Prescribing medications to reduce the effects of the hallucinogenic drugs
- Referring the patient to a support group for further assistance
10 Days of Hospitalization Required
Average Time for Outpatient Care Not Established
Psychodysleptics [hallucinogens] - Prevention
Prevention of psychodysleptics [hallucinogens] involves educating individuals on the risks of use, providing support for those at risk of using, and encouraging individuals to seek help if they are already using. additionally, providing resources and support to those who are already using and helping them to identify potential triggers and develop strategies for avoiding use can help to prevent further use.